Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.452 - Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study
D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review
D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials
D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy
D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update
D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre
D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study
D1.451 - Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma
D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
D2.460 - Does Aspirin change outcomes of dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download